壳寡糖对非酒精性脂肪性肝病的保护作用

肝脏 ›› 2025, Vol. 30 ›› Issue (1): 91-94.

壳寡糖对非酒精性脂肪性肝病的保护作用

赵康涛, 黄文琪, 林颖珺, 孙丽, 赵坐都, 黄宗锈, 吴珍红, 郑丽红, 林云, 韩尧跃, 林秀芬

350012 福州福建省疾病预防控制中心(赵康涛,黄宗锈,吴珍红,郑丽红,林云);厦门弘爱医院(黄文琪);上海交通大学药学院(林颖珺);厦门蓝湾科技有限公司(孙丽,赵坐都,韩尧跃,林秀芬)

收稿日期:2023-11-28 出版日期:2025-01-31 发布日期:2025-03-10
通讯作者: 韩尧跃,Email: hanyy@bluebayst.com

Protective effect of chitosan oligosaccharides on nonalcoholic fatty liver disease

ZHAO Kang-tao, HUANG Wen-qi, Lin Ying-jun, SUN li, ZHAO Zuo-dou, HUANG Zong-xiu, WU Zhen-hong, ZHENG Li-hong, LIN Yun, HAN Yao-yue, LIN Xiu-fen

1. Fujian Center for Disease Control and Prevention (Fujian Academy of Preventive Medicine), Fuzhou 350001, China;
2. Xiamen Humanity Hospital, Fujian 361009, China;
3. School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China;
4. Xiamen Bluebay Science and Technology Co.,Ltd., Fujian 361026, China

Received:2023-11-28 Online:2025-01-31 Published:2025-03-10
Contact: HAN Yao-yue,Email: hanyy@bluebayst.com

摘要/Abstract

摘要： 目的探讨高含量、高脱乙酰度壳寡糖对非酒精性脂肪肝小鼠的辅助保护作用。方法将75只KM小鼠随机分为5组:3个样品试验组、模型组、阴性对照组。样品试验组和模型组每日摄入高脂饲料,阴性对照组予以常规饲料连续8周。第9周开始连续30 d经口灌胃样品试验组低(0.125 g)、中(0.25 g)、高(0.75 g)剂量的壳寡糖,阴性对照组和模型对照组给予等量纯水。在第31天处死动物,采血清测肝功能,观察肝组织外观性状并进行组织病理学检查。同时取部分肝组织匀浆,测定TG、GSH、MDA、TNF-α、TGF-β、IL-6等含量的变化。结果经口灌胃小鼠不同剂量的壳寡糖30 d后,中剂量组小鼠肝组织中的AST、TGF-β、TNF-α分别为(68.0±5.4)U/L、(62±5.0)pg/mL、(52±3.0)pg/mL,高剂量组肝组织中的TG(0.25±0.15)mmol/L、MDA(2.3±0.75) nmol/L、IL-6(2.8±0.3)pg/mL、ALT(35.5±2.7)U/L,模型组AST(89.5±9.4)U/L、TGF-β(75±4.2)pg/mL、TNF-α(60±5.3)pg/mL、TG(0.3±0.1)mmol/L(P<0.05);中、高剂量组GSH含量分别为(2.0±0.4)μmol/gprot和(2.1±0.8)μmol/gprot,较模型组的(1.5±0.9)μmol/gprot有所升高(P<0.05)。肝脏病理学检查结果表明:中、高剂量组小鼠体内肝脏中的脂滴分布范围小于模型组且面积积分低于模型对照组(P<0.05)。结论高含量、高脱乙酰度壳寡糖对非酒精性脂肪肝有辅助保护作用。

关键词: 非酒精性脂肪性肝病, 炎症, 壳寡糖, 免疫, 肝功能, 抗氧化

Abstract: Objective To study the protective effect of chitosan oligosaccharides on mouse nonalcoholic fatty liver disease. Methods 75 KM mice were randomly divided into 5 groups. Three sample groups and the model group were given with a high-fat diet daily for 8 weeks, while the negative group was given ordinary diet consecutively. Three sample groups of mice were given different doses of samples by oral gavage for 30 days after nine weeks. The animals of the negative control group and the model control group were simultaneously given equal amounts of pure water. At the end of the experiment, the animals were weighed and fasted for 16 hours. On the 31st day, the animals were anesthetized and killed. Blood samples were collected. We performed anatomical observation and histopathology examination on the liver tissue. Simultaneously take some liver tissue homogenate and examine changes in levels of TG, GSH, MDA, TNF-α、TGF-β and IL-6 in it. Methods After administering different doses of chitosan oligosaccharides to mice by oral gavage for 30 days ,the level of AST, TGF-β and TNF-α (68.0±5.4 U/L, 62±5.0 pg/mL, 52±3.0 pg/mL)in liver tissue of medium dose group,and the level of TG(0.25±0.15 mmol/L), MDA(2.3±0.75 nmol/L), IL-6(2.8±0.3 pg/mL), ALT(35.5±2.7 U/L) in the liver tissue of high-dose groups are decreased(AST 89.5±9.4 U/L,TGF-β 75±4.2 pg/mL, TNF-α 60±5.3 pg/mL, TG 0.3±0.1 mmol/L)(P<0.05)compared with the model group, while the concentration of GSH in the medium and high-dose groups (Medium 2.0±0.4 μmol/gprot , High-dose 2.1±0.8 μmol/gprot) is increased (P<0.05) , the results of liver pathology examination showed that the distribution, range, and area of lipid droplets in the medium and high-dose groups were lower than those in the model control group (P<0.05). Conclusion Chitosan oligosaccharides display an auxiliary protective effect on non-alcoholic fatty liver disease.

Key words: Nonalcoholic fatty liver disease, Inflammation, Chitosan oligosaccharides, Immunity, Liver function, Antioxidant

赵康涛, 黄文琪, 林颖珺, 孙丽, 赵坐都, 黄宗锈, 吴珍红, 郑丽红, 林云, 韩尧跃, 林秀芬. 壳寡糖对非酒精性脂肪性肝病的保护作用[J]. 肝脏, 2025, 30(1): 91-94.

ZHAO Kang-tao, HUANG Wen-qi, Lin Ying-jun, SUN li, ZHAO Zuo-dou, HUANG Zong-xiu, WU Zhen-hong, ZHENG Li-hong, LIN Yun, HAN Yao-yue, LIN Xiu-fen. Protective effect of chitosan oligosaccharides on nonalcoholic fatty liver disease[J]. Chinese Hepatolgy, 2025, 30(1): 91-94.

/ 推荐

参考文献

[1] 郭蔓,赵华,张朝正等,壳寡糖的制备及应用研究[J].中国食品添加剂.2022, 33(10):267-271.
[2] MuhamnadN, Luca P, Muhammad S, et al. Chitosan oligosaccharide (cos): An overview[J]. Int J Biol Macromol., 2019, (129):827-843.
[3] ShiL, Fang B, Yong Y, et al. Chitosan oligosaccharide mediated attenuation of LPS-induced inflammation in IPEC-J2 cells is related to the TLR4/NF-κB signaling pathway[J]. Carbohydr Polymers, 2019, (219):269-279.
[4] 朱小花, 赵利敏, 王荣辉等, 壳寡糖抑菌及抗肿瘤活性研究[J]. 食品安全质量检测学报. 2022,13(6): 1726-1731.
[5] 赵丹莉, 谢明杰. 高通量测序技术分析壳寡糖对小鼠肠道菌群的影响[J]. 营养学报, 2018, 40(5): 449-453.
[6] YuY, Luo T, Liu S, et al. Chitosan oligosaccharides attenuate atherosclerosis and decrease non-HDL in ApoE-/-mice[J]. J Atheroscler Thromb, 2015, 22(9): 926-941.
[7] KumarA. The virtuous potential of chitosan oligosaccharide for promising biomedical applications[J]. J Mater Res,2020, 35(9): 1123-1134.
[8] 杨焕蝶, 张翔, 亚历山大等. 壳聚糖与壳寡糖抑菌保鲜研究进展[J].山东农业科学, 2020, 52(2): 167-172.
[9] GohGB,McCullough AJ. Natural history of nonalcoholic fatty liver disease[J]. Dig Dis Sci,2016,61(5):1226-1233.
[10] 张园园,周希乔.肠道菌群与非酒精性脂肪肝研究进展[J].中华消化杂志,2016,36(11):790-792.
[11] 陈一平,肖百全,张景鸿等,新型非酒精性脂肪肝模型建立及免疫细胞机制探讨[J].中国药理学通报.2018;34(6):882-886.
[12] SunB,Karin M.Obesity,inflammation,and liver cancer[J]. J Hepatol,2012,56(3): 704.
[13] StaufferJK,Scarzello AJ,Jiang Q,et al. Chronic inflammation,immune escape,and oncogenesis in the liver: a unique neighborhood for novel intersections[J]. Hepatology,2012,56(4):1567.
[14] XieJ,Yang L,Tian L,et al.Macrophage migration inhibitor factor upregulates MCP-1 expression in an autocrine manner in hepatocytes during acute mouse liver injury[J].Sci Rep,2016,(6): 27665.
[15] 杨靖亚,郑雯静,李诗怡.壳寡糖的制备及生物活性研究进展[J].国际药学研究杂志. 2020,47(7):502-507.
[16] DowmanJK,Tomlinson JW,Newsome PN. Systematic review:the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther,2011,33( 5):525-540.
[17] AhmedM. Non-alcoholic fatty liver disease in 2015[J]. World J Hepatol,2015,7( 11) : 1450- 1459.
[18] 祝娟娟,程明亮,赵雪珂,肝脏免疫炎症在非酒精性脂肪性肝病发生发展中的作用[J].临床肝胆病杂志,2016,32(3): 570-573.